<ul><li>Umoja Biopharma secured series C funding to advance its oncology pipeline, highlighting the growing momentum behind in vivo therapies.</li><li>In vivo gene delivery is gaining acceptance as recent developments suggest a changing mindset among innovators and investors.</li><li>In vivo therapies offer a cost-effective alternative to ex vivo treatments, potentially transforming access to cutting-edge treatments.</li><li>The shift towards in vivo therapies holds the promise of changing how diseases are treated globally and making life-saving options more accessible.</li></ul>

Discovering the Next Big Wave

Discover more